Business
Lynparza nearly doubled time patients lived with
Lynparza nearly doubled time patients lived with.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \nRNS Number : 8502A AstraZeneca PLC 03 June 2019 \n\n \nLynparza nearly doubled the time patients lived without disease progression from germline BRCA-mutated metastatic pancreatic cancer\n \n22% of patients receiving Lynparza remained free of\ndisease progression after two years vs. 10% on placebo\n \nLynparza now the first PARP inhibitor to\ndemonstrate benefit in three different cancer types\n \n3 June 2019 07:00 BST\n \nAstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced detailed results from the Phase III POLO trial at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US (Abs #LBA4). Results are today also published in The New England Journal of Medicine (NEJM).\n \nThe POLO trial tested Lynparza (olaparib) tablets as 1st-line maintenance monotherapy for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose disease had not progressed following standard-of-care platinum-based 1st-line chemotherapy.\n \nResults from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for Lynparza vs. placebo, improving the time without disease progression by a median of 7.4 months for patients treated with Lynparza vs. 3.8 months for those on placebo (HR 0.53 [95% CI, 0.35-0.82], p=0.004). More than twice as many patients showed no disease progression both at one year (34% on Lynparza vs. 15% on placebo) and two years (22% vs. 10%, respectively).\n \nJosé Baselga, Executive Vice President, Oncology R&D, said: \"These unprecedented results raise new hope for patients that have seen little progress over a long period of time. From as early as six months after initiation, more than twice as many patients taking Lynparza lived without progression of their disease compared to those on placebo and we are now working with regulatory authorities to bring Lynparza to patients as quickly as possible.\" \n \nRoy Baynes, Senior Vice President and Head of Global Clinical Development, Chief Medical Officer, MSD Research Laboratories, said: \"We are encouraged by the results of the POLO trial which showed a considerable reduction in risk of disease progression or death with...